T1	Participants 379 430	patients previously treated with a fluoropyrimidine
T2	Participants 525 569	hemotherapy and irinotecan in these patients
T3	Participants 620 975	patients with advanced colorectal cancer were randomly allocated to: Combination therapy (FOLFIRI), irinotecan (180 mg/m(2) IV over 90 min, day 1), 5-fluorouracil (400mg/m(2) IV bolus and 2400 mg/m(2) by 46-hour infusion from day 1) and folinic acid (20mg/m(2) IV bolus, day 1), 2-weekly; or Single-agent, irinotecan (350 mg/m(2) IV over 90 min), 3-weekly
T4	Participants 1275 1324	44 patients to combination and 45 to single agent
T5	Participants 1326 1423	Eight patients in the irinotecan arm and 4 in the combination arm had grade 3/4 diarrhoea (P=0.24
